First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer

This first-in-human study is testing a new diagnostic and treatment pairing for pancreatic cancer. A special imaging agent helps doctors see the cancer on a PET scan, and a companion radioactive drug is then used to deliver targeted radiation directly to the tumor. Researchers are evaluating whether this approach is safe and effective. **You may be eligible if you:** - Are 18 years of age or older - Have confirmed advanced, unresectable, or metastatic pancreatic adenocarcinoma (the most common type of pancreatic cancer) - Have measurable disease on scans - Have had at least one prior treatment regimen that your cancer progressed on - Are in reasonably good health (ECOG performance status of 0–2) **You may NOT be eligible if you:** - Have not tried any prior treatment for your pancreatic cancer - Have very poor organ function (kidneys, liver, bone marrow) - Are not able to come off recent chemotherapy before starting this study Talk to your doctor to see if this trial is right for you.